[Skip to Content]
[Skip to Content Landing]
Editorial
September 14, 2009

SCOREing in Retinal Venous Occlusive Disease

Arch Ophthalmol. 2009;127(9):1203-1204. doi:10.1001/archophthalmol.2009.226

Retinal venous occlusive disease, including branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), is the second most common cause of severe vision loss in the United States.1,2 Vision loss in retinal venous occlusive disease can occur from macular edema, ischemia, or neovascular glaucoma. The Branch Retinal Vein Occlusion Study has demonstrated that in a subset of patients with nonischemic macular edema grid laser photocoagulation significantly reduced the risk of moderate to severe vision loss and also improved the possibility of visual gain.1 The Central Retinal Vein Occlusion Study demonstrated that for macular edema associated with CRVO grid laser photocoagulation was no better than observation.3 These studies have been used as the gold standard for providing natural history information as well as treatment paradigms in the management of BRVO and CRVO.

First Page Preview View Large
First page PDF preview
First page PDF preview
×